Home › Leucemia linfatica cronica › North Carolina › Charlotte
Studi clinici su Leucemia linfatica cronica a Charlotte, NC
9 studi su Leucemia linfatica cronica cercano partecipanti presso sedi a Charlotte e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
In reclutamentoFase 1/2
- Research Site, Charlotte
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
In reclutamentoFase 3
- Atrium Health Levine Cancer Institute (Lci), Charlotte
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
In reclutamentoFase 3
- Levine Cancer Center, Charlotte
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
In reclutamentoFase 3
- Atrium Health Levine Cancer Institute (Lci), Charlotte
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
In reclutamentoFase 3
- Carolina Oncology Specialists, PA ( Site 0054), Charlotte
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
In reclutamentoFase 1/2
- Research Site, Charlotte
- Research Site, Charlotte
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
In reclutamentoFase 2
- Research Site, Charlotte
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
In reclutamentoFase 3
- Atrium Health /ID# 267219, Charlotte
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
In reclutamentoFase 2
- Novant Health Presbyterian Medical Center /ID# 230201, Charlotte
Studi su Leucemia linfatica cronica in altre città
- Boston, MA31 studi
- Columbus, OH28 studi
- Durham, NC27 studi
- Washington, DC22 studi
- Seattle, WA20 studi
- New York City, NY18 studi
- Rochester, MN18 studi
- Houston, TX17 studi
- Baldwin Park, CA16 studi
- Milwaukee, WI15 studi
- Chicago, IL14 studi
- Cincinnati, OH14 studi
Altri studi a Charlotte
- Cancro (tutti i tipi)27 studi
- Cancro al seno22 studi
- Mieloma multiplo21 studi
- Cancro del polmone non a piccole cellule19 studi
- Leucemia mieloide acuta16 studi
- Obesità16 studi
- Sovrappeso15 studi
- Cancro colorettale13 studi
- Cancro ovarico12 studi
- Insufficienza cardiaca11 studi
- Cancro metastatico11 studi
- Carcinoma a cellule squamose della testa e del collo10 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.